MINERALOCORTICOID RECEPTOR ANTAGONISTS THERAPY IN RESISTANT HYPERTENSION: TIME TO IMPLEMENT NEW GUIDELINES?

Despite the availability of anti-hypertensive medications with increasing efficacy up to 50% of hypertensive patients have blood pressure levels (BP) not at the goals set by international societies. Some of these patients are either not optimally treated or are non adherent to the prescribed drugs,...

Full description

Bibliographic Details
Published in:	Frontiers in Cardiovascular Medicine
Main Authors:	Giuseppe eMaiolino, Matteo eAzzolini, Gian Paolo eRossi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2015-02-01
Subjects:	therapy Pathogenesis review Resistant hypertension Mineralocorticoid Receptor Antagonists
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fcvm.2015.00003/full

Similar Items

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

Heart failure: the role for mineralocorticoid receptor antagonists
by: Bertram Pitt
Published: (2014-05-01)

In Silico Investigation of Mineralocorticoid Receptor Antagonists: Insights into Binding Mechanisms and Structural Dynamics
by: Julia J. Liang, et al.
Published: (2025-03-01)

Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue
by: WEN Runzhi, WANG Li, ZHAO Naiqian
Published: (2025-06-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01)

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases
by: Jiao Wang, et al.
Published: (2025-08-01)

Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists
by: Biykem Bozkurt, et al.
Published: (2025-07-01)

Steroidal Mineralocorticoid Receptor Antagonist Side Effects and Reasons for Discontinuation: A Patient Survey (RELICS-PS)
by: Richard EL, et al.
Published: (2025-04-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021-06-01)

Assessment of renal and cardiovascular risks in patients with type 2 diabetes when using non-steroidal mineralocorticoid receptor antagonists
by: V.М. Yerokhovych, et al.
Published: (2023-12-01)

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
by: S N Tereshchenko, et al.
Published: (2013-12-01)

A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
by: Shuhui Zhai, et al.
Published: (2024-09-01)

The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist’s treatment: A review
by: Irina N. Bobkova
Published: (2023-11-01)

Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients
by: Takuro Abe, et al.
Published: (2020-10-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
by: A. M. Esayan, et al.
Published: (2018-04-01)

Effectiveness and safety of mineralocorticoid receptor antagonists in heart failure patients with and without diabetes: a systematic review and meta-analysis
by: Arga Setyo Adji, et al.
Published: (2024-11-01)

Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice
by: Maria Alfarano, MD, PhD, et al.
Published: (2025-06-01)

Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment
by: Mohamad El Wardani, et al.
Published: (2023-03-01)

Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review
by: Kisho Miyasako, et al.
Published: (2024-12-01)

Endogenous bufadienolides, mineralocorticoid receptor antagonists and fibrosis in chronic kidney disease
by: Mai Rosenberg, et al.
Published: (2024-09-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
by: O. A. Osipova, et al.
Published: (2021-11-01)

Mineralocorticoid receptor antagonists reduce inflammatory signaling independent of myofiber mineralocorticoid receptor
by: Jeovanna Lowe, et al.
Published: (2025-12-01)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
by: Memory MUKANGWA, et al.
Published: (2019-12-01)

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease
by: Ixchel Lima Posada, et al.
Published: (2024-06-01)

Adrenal venous sampling outcomes with and without mineralocorticoid receptor antagonists in primary aldosteronism
by: Sittikul Thipbumrung, et al.
Published: (2025-07-01)

Chemokine receptor CXCR7 antagonism ameliorates cardiac and renal fibrosis induced by mineralocorticoid excess
by: Bing H. Wang, et al.
Published: (2024-11-01)

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis
by: Chien‐Wei Huang, et al.
Published: (2025-02-01)

Vascular cell‐specific roles of mineralocorticoid receptors in pulmonary hypertension
by: Divya P. Menon, et al.
Published: (2021-07-01)

Apparent mineralocorticoid excess - A rare cause of endocrine hypertension
by: Sonali Verma, et al.
Published: (2022-01-01)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
by: Ulrich Kintscher, et al.
Published: (2023-06-01)

Clinical application of mineralocorticoid receptor antagonists in chronic heart failure
by: MG Bubnova
Published: (2014-12-01)

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?
by: Houry Puzantian, et al.
Published: (2024-12-01)

Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat
by: Chang Geng, et al.
Published: (2023-11-01)

Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis
by: Yue Zhang, et al.
Published: (2025-09-01)

FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes
by: M. S. Shamkhalova, et al.
Published: (2023-12-01)

Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials
by: Paula Dibo, et al.
Published: (2025-08-01)

Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials
by: Jinfei Wu, et al.
Published: (2025-09-01)

Treatment Patterns, Adverse Events, and Clinical Outcomes with Steroidal Mineralocorticoid Receptor Antagonists: A Retrospective Analysis of Administrative Claims Data (RELICS)
by: Richard EL, et al.
Published: (2025-02-01)

Therapeutic Potential of Mineralocorticoid Receptors in Skeletal Muscle Aging
by: Ricardo Aparecido Baptista Nucci, et al.
Published: (2025-07-01)

Efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists for renal and cardiovascular outcomes in patients with chronic kidney disease: a meta-analysis of randomized clinical trials
by: Qianlan Chen, et al.
Published: (2024-02-01)